Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Biofrontera Inc. (BFRI)

0.6   -0.02 (-3.23%) 03-27 16:00
Open: 0.6477 Pre. Close: 0.62
High: 0.6477 Low: 0.5801
Volume: 40,954 Market Cap: 16(M)

Technical analysis

as of: 2023-03-27 4:17:41 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 0.83     One year: 0.95
Support: Support1: 0.55    Support2: 0.45
Resistance: Resistance1: 0.71    Resistance2: 0.81
Pivot: 0.61
Moving Average: MA(5): 0.6     MA(20): 0.62
MA(100): 0.86     MA(250): 1.57
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 40.7     %D(3): 36
RSI: RSI(14): 36.7
52-week: High: 6.11  Low: 0.55
Average Vol(K): 3-Month: 117 (K)  10-Days: 56 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BFRI ] has closed above bottom band by 41.0%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.62 - 0.63 0.63 - 0.63
Low: 0.58 - 0.59 0.59 - 0.59
Close: 0.61 - 0.62 0.62 - 0.63

Company Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Headline News

Mon, 27 Mar 2023
Biofrontera Inc. (BFRI) Makes Transformative Investment in Its ... -

Fri, 17 Mar 2023
Why Sarepta Therapeutics Shares Are Trading Lower By Around 19 ... - UK

Fri, 17 Mar 2023
Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting - Yahoo Finance

Thu, 09 Mar 2023
Benchmark Reaffirms Buy Rating and $7 Price Target for Biofrontera - Best Stocks

Thu, 09 Mar 2023
Biofrontera Inc. (NASDAQ:BFRI) Q4 2022 Earnings Call Transcript - Yahoo Finance

Thu, 02 Mar 2023
Biofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023 - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 27 (M)
Shares Float 15 (M)
% Held by Insiders 42.3 (%)
% Held by Institutions 7.4 (%)
Shares Short 236 (K)
Shares Short P.Month 386 (K)

Stock Financials

EPS -0.03
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.88
Profit Margin (%) -2.3
Operating Margin (%) -75.1
Return on Assets (ttm) -25.9
Return on Equity (ttm) -3.7
Qtrly Rev. Growth 10.6
Gross Profit (p.s.) 0.5
Sales Per Share 1.07
EBITDA (p.s.) -0.79
Qtrly Earnings Growth 0
Operating Cash Flow -16 (M)
Levered Free Cash Flow 2 (M)

Stock Valuations

PE Ratio -20.01
PEG Ratio 0
Price to Book value 0.67
Price to Sales 0.55
Price to Cash Flow -0.99

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.